Endoscopic Submucosal Dissection Market

7500+ companies worldwide approach us every year for their revenue growth initiatives
Global top 2000 strategist rely on us for their growth strategies.
80% of fortune 2000 companies rely on our research to identify new revenue sources.
30000 High Growth Opportunities
95% renewal rate
KNOW MORE
  1. HOME
  2. Top Market Reports
  3. Endoscopic Submucosal Dissection Market

Endoscopic Submucosal Dissection Market by Product (Grasp, Clips, Gastroscopes, Colonoscopes), Indication (Cancer (Esophageal, Stomach, Colon), End User (Hospitals, Ambulatory Surgical Centers, Specialty Clinics) & Region - Global Forecasts to 2027

FREE BROCHURE FREE SAMPLE REPORT
Report Code: MD 8538 Jan, 2023, by marketsandmarkets.com

Updated on : February 15, 2023

The global endoscopic submucosal dissection market in terms of revenue was estimated to be worth $347 million in 2022 and is poised to reach $483 million by 2027, growing at a CAGR of 6.9% from 2022 to 2027. The rising incidence of target diseases such as cancer is expected to accelerate the need for endoscopic procedures, which, in turn, will propel the growth of this market in the coming years. Due to the high capital, training, and maintenance costs, endoscopic submucosal dissection procedures are generally expensive. Also, in most Asian countries, there is limited or no reimbursement for endoscopic submucosal dissection procedures from governments, which is expected to restrain market growth to a certain extent in the coming years.

Endoscopic Submucosal Dissection Market

To know about the assumptions considered for the study, Request for Free Sample Report

Endoscopic Submucosal Dissection Market Dynamics

Driver: Growing geriatric population

Rising age-related diseases, such as gastric cancer and gastrointestinal (GI) bleeding, are driving demand for endoscopic submucosal dissection (ESD). The aging population is more prone to these diseases, due to its weakened immune system and decreased physical activity. The number of people aged 65 and over is expected to reach 1.5 billion by 2050, which will fuel the demand for endoscopic submucosal dissection. The rising prevalence of cancer is also contributing to the growth of the endoscopic submucosal dissection market.

Restraint: High overhead cost of ESD procedures with limited reimbursements

The high overhead cost of ESD procedures with limited reimbursements is a major restraint to the growth of the endoscopic submucosal dissection market. This is because endoscopic submucosal dissection is a complex and time-consuming procedure and the costs associated with it are quite high. This makes the procedure unaffordable for many patients. Additionally, the reimbursement levels for endoscopic submucosal dissection are quite low, which is another major factor preventing its adoption. This factor is particularly prominent in developing countries where the healthcare infrastructure is not well-developed.

Opportunity: Expected increase in adoption of and preference for endoscopic submucosal dissection procedures in developing countries

The rise of endoscopic submucosal dissection (ESD) procedures in developing countries is expected to drive the growth of the global endoscopic submucosal dissection market. This is due to the increasing affordability of endoscopy procedures and the availability of cost-effective equipment in these markets. Additionally, the growing awareness of ESD procedures and the availability of skilled personnel in these countries are expected to further drive the market growth.

The rising prevalence of gastrointestinal disorders, such as esophageal and gastric cancer, is likely to propel the demand for ESD procedures in developing nations. Increased government focus on healthcare infrastructure and improvements in healthcare access, such as the implementation of universal healthcare systems, are expected to further drive the growth of the market. Additionally, the increasing focus of medical device manufacturers on expanding their presence in these markets is likely to provide a major boost to the market growth.

Furthermore, the growing number of mergers and acquisitions, strategic collaborations, and product launches by market players is expected to create lucrative opportunities for the growth of the global endoscopic submucosal dissection market.

Challenges: Risk of post-operative infection

Endoscopic submucosal dissection is a relatively new procedure used for the treatment of early gastrointestinal cancers, regardless of lesion size and configuration. It has gradually acquired popularity because of its minimally invasive nature. As compared to conventional endoscopic resection, endoscopic submucosal dissection is a more complex procedure and requires a higher level of technical skill. Therefore, it is associated with a higher complication rate. Post-operative fever is one of the most common complications. During ESD, the injection needle catheter is passed through the contaminated endoscopic channel and may directly inoculate bacteria into the bloodstream during the submucosal injection. In addition, ESD can produce mucosal defects. Bacteremia and/or endotoxemia can occur when submucosal and muscularis propria cells are exposed to native bacterial flora in the gastrointestinal tract. Bacteremia could be caused by the bacterial translocation of endogenous microbial flora through the injured mucosa into the bloodstream during the endoscopy procedure. These infectious complications have been reported to be infrequent and transient in both EMR and ESD of the stomach and colon.

Based on product, the knives segment will grow at the highest CAGR in the endoscopic submucosal dissection market during the forecast period.

Based on product, the market is segmented into knives, tissue retractors, graspers/clips, injection agents, gastroscopes and colonoscopes, and other products. The knives segment will continue to dominate the market in 2027, growing at the highest CAGR during the forecast period. In endoscopic submucosal dissection, lesions are circumscribed with a knife to free the lesion completely from the rest of the normal mucosa. There are a variety of knives available in the market, and the field has evolved rapidly over the past two decades with efforts to improve efficacy, safety, and cost-effectiveness.

Based on indications, the esophageal cancer segment will grow at the highest CAGR in the endoscopic submucosal dissection market during the forecast period.

Based on indication, the market is segmented into stomach cancer, colon cancer, and esophageal cancer. The esophageal cancer segment will grow at the highest CAGR during the forecast period. The incidence of superficial esophageal cancer (SEC) is increasing, particularly in Asian countries, including Japan, where screening for upper digestive tract cancers is common.

Based on end user, the hospitals segment will grow at the highest CAGR in the endoscopic submucosal dissection market during the forecast period.

In 2021, the hospitals segment will grow at the highest CAGR during the forecast period. Investments and incentives received by hospitals from government bodies are few key factors for the growth of this segment.

Endoscopic Submucosal Dissection Market by Region

To know about the assumptions considered for the study, download the pdf brochure

North America is expected to account for the largest share of the endoscopic submucosal dissection market in 2021.

North America is expected to account for the largest share, and its dominance in the global market is mainly attributed to the high healthcare spending in the country, favourable reimbursement policies for endoscopic procedures, an increased incidence of cancer, constant research on endoscopy techniques, and a high number of FDA approvals for endoscopy systems in the US.

The prominent players in the endoscopic submucosal dissection market are Olympus Corporation (Japan), Boston Scientific Corporation (US), FUJIFILM Holdings Corporation (Japan), Sumitomo Bakelite Co., Ltd. (Japan), Creo Medical (UK), Medtronic (Ireland), MTW Endoskopie Manufaktur (Germany), HOYA Corporation (Japan), Ovesco Endoscope AG (Germany), Zeon Medical Inc. (Japan), KARL STORZ SE & Co. KG (Germany), ConMed Corporation (US), Micro-tech Endoscopy (China), Cook Group (US), Steris PLC (Ireland), Leo Medical Co., Ltd. (China), Erbe Elektromedizin GmbH (Germany), Taewoong Medical (South Korea), DCC Healthcare (Ireland), Kossen Co., Ltd. (South Korea), Innova Medica SPA (Italy), Jiangsu Vedkang Medical Science and Technology Co., Ltd. (China), Hangzhou AGS MedTech Co., Ltd. (China), and Beijing ZKSK Technology Co., Ltd. (China).

Endoscopic Submucosal Dissection Market Report Scope

Report Metric

Details

Market Revenue in 2022

$347 million

Estimated Value by 2027

$483 million

Growth Rate

poised to grow at a CAGR of 6.9%

Market Segmentation

Product, Indication, End User & Region

Market Drivers
  • Increasing use of endoscopy in detection and treatment procedures
  • Rising prevalence of cancer
  • Growing geriatric population

Market Opportunities
  • Growing demand for minimally invasive procedures
  • Growing investments in research and development of endoscopy technology
  • Expected increase in adoption of and preference for endoscopic submucosal dissection procedures in developing countries

Geographies covered

North America, Europe, APAC, MEA, and Latin America

This report categorizes the global endoscopic submucosal dissection market into the following segments and subsegments:

By Product

  • Gastroscopes And Colonoscopes
  • Knives
  • Injection Agents
  • Tissue Retractors
  • Graspers/Clips
  • Other Products

By Indication

  • Stomach Cancer
  • Colon Cancer
  • Esophageal Cancer

By End User

By Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Rest of Asia Pacific
  • Latin America
  • Middle East and Africa

Recent Developments

In recent years, Endoscopic Submucosal Dissection (ESD) has become increasingly popular as a therapeutic option for resecting early gastric cancers. ESD is a minimally invasive endoscopic procedure that uses a special knife and suction device to cut and remove cancerous or precancerous tissue from the gastrointestinal tract. It is a safe, effective, and highly precise method of removing tumors from the stomach, esophagus, and rectum without the need for major surgery. Compared to other therapies such as endoscopic mucosal resection, ESD is more accurate and results in less bleeding and shorter recovery times. It has also been shown to be effective in treating early gastric cancer, reducing gastric cancer mortality rates. In addition, it has been used to treat early colorectal cancer, benign lesions, and dysplasia with high success rates. With its increasing use, ESD is revolutionizing the treatment of early gastric and colorectal cancers and other gastrointestinal diseases.

  • In March 2021, FUJIFILM Holdings Corporation (Japan) acquired Diagnostic Imaging-related Business (the Business), Hitachi, Ltd.. This acquisition helped in the expansion of the medical systems business of FUJIFILM Corporation.
  • In January 2021, Olympus Corporation (Japan) acquired Quest Innovations B.V. (Netherlands). The acquisition enabled Olympus to strengthen its surgical endoscopy capabilities and incorporate Quest’s advanced FIS capabilities into its comprehensive medical imaging portfolio.
  • In November 2020, Creo Medical Group PLC (UK) acquired Boucart Medical SRL (Belgium). Creo Medical Group completed the acquisition of Boucart Medical SRL, the largest independent supplier of gastrointestinal endoscopy consumables in Belgium and Luxembourg.

Frequently Asked Questions (FAQs):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS
 
1 INTRODUCTION (Page No. - 26)
    1.1 STUDY OBJECTIVES 
    1.2 MARKET DEFINITION 
           1.2.1 INCLUSIONS AND EXCLUSIONS
    1.3 MARKET SCOPE 
           1.3.1 MARKETS COVERED
                    FIGURE 1 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SEGMENTATION
    1.4 YEARS CONSIDERED 
    1.5 CURRENCY CONSIDERED 
          TABLE 1 STANDARD CURRENCY CONVERSION RATES
    1.6 SCOPE-RELATED LIMITATIONS 
    1.7 STAKEHOLDERS 
 
2 RESEARCH METHODOLOGY (Page No. - 31)
    2.1 RESEARCH DATA 
          FIGURE 2 RESEARCH DESIGN
           2.1.1 SECONDARY DATA
                    2.1.1.1 Key data from secondary sources
           2.1.2 PRIMARY DATA
                    FIGURE 3 PRIMARY SOURCES
                    2.1.2.1 Key data from primary sources
                    2.1.2.2 Key industry insights
                                FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
                                FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION
                                FIGURE 6 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY END USER, DESIGNATION, AND REGION
    2.2 MARKET SIZE ESTIMATION 
          FIGURE 7 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
          FIGURE 8 REVENUE SHARE ANALYSIS ILLUSTRATION: OLYMPUS CORPORATION
          FIGURE 9 SUPPLY-SIDE MARKET SIZE ESTIMATION: GLOBAL MARKET (2021)
          FIGURE 10 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2022–2027)
          FIGURE 11 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
          FIGURE 12 TOP-DOWN APPROACH
    2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 
          FIGURE 13 DATA TRIANGULATION METHODOLOGY
    2.4 MARKET SHARE ESTIMATION 
    2.5 STUDY ASSUMPTIONS 
    2.6 METHODOLOGY-RELATED LIMITATIONS 
    2.7 RISK ASSESSMENT 
          TABLE 2 RISK ASSESSMENT: GLOBAL MARKET
 
3 EXECUTIVE SUMMARY (Page No. - 45)
    FIGURE 14 GLOBAL MARKET, BY PRODUCT, 2022 VS. 2027 (USD MILLION)
    FIGURE 15 GLOBAL MARKET, BY INDICATION, 2022 VS. 2027 (USD MILLION)
    FIGURE 16 GLOBAL MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)
    FIGURE 17 GEOGRAPHIC SNAPSHOT OF GLOBAL MARKET
 
4 PREMIUM INSIGHTS (Page No. - 48)
    4.1 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET OVERVIEW 
          FIGURE 18 INCREASING USE OF ENDOSCOPY IN DETECTION AND TREATMENT PROCEDURES TO DRIVE MARKET GROWTH
    4.2 ASIA PACIFIC: MARKET, BY PRODUCT AND COUNTRY 
          FIGURE 19 GASTROSCOPES AND COLONOSCOPES HELD LARGEST SHARE OF ASIA PACIFIC MARKET IN 2021
    4.3 GLOBAL MARKET: GEOGRAPHIC MIX 
          FIGURE 20 MARKET IN ASIA PACIFIC TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD
    4.4 GLOBAL MARKET: REGIONAL MIX 
          FIGURE 21 NORTH AMERICA TO BE LARGEST MARKET FOR ENDOSCOPIC SUBMUCOSAL DISSECTION PRODUCTS THROUGHOUT FORECAST PERIOD
    4.5 GLOBAL MARKET: DEVELOPED VS. DEVELOPING MARKETS 
          FIGURE 22 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH RATE DURING FORECAST PERIOD
 
5 MARKET OVERVIEW (Page No. - 52)
    5.1 INTRODUCTION 
    5.2 MARKET DYNAMICS 
          FIGURE 23 GLOBAL MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.2.1 DRIVERS
                    5.2.1.1 Increasing use of endoscopy in detection and treatment procedures
                    5.2.1.2 Rising prevalence of cancer
                                FIGURE 24 GLOBAL CANCER INCIDENCE, 2008–2030
                    5.2.1.3 Growing geriatric population
                                FIGURE 25 SHARE OF GERIATRIC POPULATION, BY REGION (2010–2030)
                                TABLE 3 GLOBAL CANCER INCIDENCE FOR GERIATRIC POPULATION (65–85+), 2020 VS. 2040
           5.2.2 RESTRAINTS
                    5.2.2.1 Dearth of skilled professionals
                    5.2.2.2 High overhead cost of ESD procedures with limited reimbursements
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Growing demand for minimally invasive procedures
                    5.2.3.2 Growing investments in research and development of endoscopy technology
                                TABLE 4 MAJOR DEVELOPMENTS
                    5.2.3.3 Expected increase in adoption of and preference for endoscopic submucosal dissection procedures in developing countries
           5.2.4 CHALLENGES
                    5.2.4.1 Higher rate of complications
                    5.2.4.2 Risk of post-operative infection
    5.3 INDUSTRY TRENDS 
           5.3.1 ADVANCES IN TRACTION METHODS FOR ENDOSCOPIC SUBMUCOSAL DISSECTION
           5.3.2 ROBOT-ASSISTED ENDOSCOPIC SUBMUCOSAL DISSECTION
    5.4 REGULATORY ANALYSIS 
           5.4.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                    TABLE 5 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                    TABLE 6 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                    TABLE 7 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
           5.4.2 NORTH AMERICA
                    5.4.2.1 US
                    5.4.2.2 Canada
           5.4.3 EUROPE
                    5.4.3.1 Germany
                    5.4.3.2 France
                    5.4.3.3 UK
                    5.4.3.4 Italy
    5.5 ECOSYSTEM MARKET MAP 
          FIGURE 26 GLOBAL MARKET: ECOSYSTEM MARKET MAP
    5.6 VALUE CHAIN ANALYSIS 
          FIGURE 27 GLOBAL MARKET: VALUE CHAIN ANALYSIS
    5.7 PORTER’S FIVE FORCES ANALYSIS 
          TABLE 8 GLOBAL MARKET: PORTER’S FIVE FORCES ANALYSIS
           5.7.1 THREAT OF NEW ENTRANTS
                    5.7.1.1 High capital requirement
                    5.7.1.2 High preference for products from well-established brands
           5.7.2 THREAT OF SUBSTITUTES
                    5.7.2.1 Presence of substitute therapies for endoscopic submucosal dissection
           5.7.3 BARGAINING POWER OF SUPPLIERS
                    5.7.3.1 Presence of several raw material suppliers
                    5.7.3.2 Supplier switching cost
           5.7.4 BARGAINING POWER OF BUYERS
                    5.7.4.1 Limited number of companies offering premium products at global level
           5.7.5 INTENSITY OF COMPETITIVE RIVALRY
                    5.7.5.1 Increasing demand for high-quality and innovative products
                    5.7.5.2 Lucrative growth potential in emerging markets
    5.8 INDICATIVE PRICING MODEL ANALYSIS 
          TABLE 9 AVERAGE SELLING PRICE, BY PRODUCT (USD)
    5.9 PATENT ANALYSIS 
           5.9.1 PATENT PUBLICATION TRENDS FOR GLOBAL MARKET
                    FIGURE 28 GLOBAL PATENT PUBLICATION TRENDS IN GLOBAL MARKET, 2015–2022
           5.9.2 TOP APPLICANTS (COMPANIES) FOR PATENTS RELATED TO ENDOSCOPIC SUBMUCOSAL DISSECTION DEVICES AND MATERIALS
                    FIGURE 29 TOP COMPANIES THAT APPLIED FOR PATENTS RELATED TO ENDOSCOPIC SUBMUCOSAL DISSECTION DEVICES AND MATERIALS, 2015–2022
           5.9.3 JURISDICTION ANALYSIS: TOP APPLICANTS (COUNTRIES) FOR PATENTS IN GLOBAL MARKET
                    FIGURE 30 JURISDICTION ANALYSIS: TOP APPLICANT COUNTRIES FOR PATENTS IN GLOBAL MARKET, 2015–2022
    5.10 SUPPLY CHAIN ANALYSIS 
          FIGURE 31 GLOBAL MARKET: STAKEHOLDERS IN SUPPLY CHAIN
    5.11 KEY CONFERENCES AND EVENTS DURING 2022–2023 
           TABLE 10 GLOBAL MARKET: DETAILED LIST OF CONFERENCES AND EVENTS
    5.12 KEY STAKEHOLDERS AND BUYING CRITERIA 
           5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS
                     FIGURE 32 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP 3 APPLICATIONS
                     TABLE 11 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP 3 APPLICATIONS
           5.12.2 BUYING CRITERIA
                     FIGURE 33 KEY BUYING CRITERIA FOR TOP 3 APPLICATIONS
                     TABLE 12 KEY BUYING CRITERIA FOR TOP 3 APPLICATIONS
 
6 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY PRODUCT (Page No. - 77)
    6.1 INTRODUCTION 
          TABLE 13 GLOBAL MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
    6.2 GASTROSCOPES AND COLONOSCOPES 
           6.2.1 RISE IN COLON CANCER INCIDENCE TO DRIVE GROWTH
                    TABLE 14 GLOBAL MARKET FOR GASTROSCOPES AND COLONOSCOPES, BY COUNTRY, 2020–2027 (USD MILLION)
    6.3 KNIVES 
           6.3.1 IMPROVED EFFICACY, SAFETY, AND COST-EFFECTIVENESS OF KNIVES TO DRIVE MARKET GROWTH
                    TABLE 15 GLOBAL MARKET FOR KNIVES, BY COUNTRY, 2020–2027 (USD MILLION)
    6.4 INJECTION AGENTS 
           6.4.1 NEED FOR LOW-COST INJECTION AGENTS TO BOOST GROWTH
                    TABLE 16 GLOBAL MARKET FOR INJECTION AGENTS, BY COUNTRY, 2020–2027 (USD MILLION)
    6.5 TISSUE RETRACTORS 
           6.5.1 RISING NUMBER OF SURGICAL PROCEDURES TO AID ADOPTION OF TISSUE RETRACTORS
                    TABLE 17 GLOBAL MARKET FOR TISSUE RETRACTORS, BY COUNTRY, 2020–2027 (USD MILLION)
    6.6 GRASPERS/CLIPS 
           6.6.1 PATIENT SAFETY AND HIGH PRECISION OFFERED BY GRASPERS TO DRIVE THEIR DEMAND
                    TABLE 18 GLOBAL MARKET FOR GRASPERS/CLIPS, BY COUNTRY, 2020–2027 (USD MILLION)
    6.7 OTHER PRODUCTS 
          TABLE 19 GLOBAL MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2020–2027 (USD MILLION)
 
7 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY INDICATION (Page No. - 85)
    7.1 INTRODUCTION 
          TABLE 20 GLOBAL MARKET, BY INDICATION, 2020–2027 (USD MILLION)
          TABLE 21 GLOBAL MARKET, BY INDICATION, 2021 (NUMBER OF PROCEDURES)
    7.2 STOMACH CANCER 
           7.2.1 STOMACH CANCER OR GASTRIC CANCER ASSOCIATED WITH SIGNIFICANT PROPORTION OF ALL CANCER DEATHS
                    TABLE 22 ESTIMATED NUMBER OF NEW CASES OF STOMACH CANCER, BY REGION (2020–2040)
                    TABLE 23 GLOBAL MARKET FOR STOMACH CANCER, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 24 GLOBAL MARKET FOR STOMACH CANCER, BY REGION, 2021 (NUMBER OF PROCEDURES)
    7.3 COLON CANCER 
           7.3.1 COLON CANCER IS THIRD-MOST-COMMON CANCER AND SECOND-LEADING CAUSE OF CANCER DEATHS WORLDWIDE
                    TABLE 25 ESTIMATED NUMBER OF NEW CASES OF COLON CANCER, BY REGION (2020–2040)
                    TABLE 26 GLOBAL MARKET FOR COLON CANCER, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 27 GLOBAL MARKET FOR COLON CANCER, BY REGION, 2021 (NUMBER OF PROCEDURES)
    7.4 ESOPHAGEAL CANCER 
           7.4.1 GROWING PREVALENCE OF ESOPHAGEAL CANCER ATTRIBUTED TO EXCESS TOBACCO AND ALCOHOL USE
                    TABLE 28 ESTIMATED NUMBER OF NEW CASES OF ESOPHAGEAL CANCER, BY REGION (2020–2040)
                    TABLE 29 GLOBAL MARKET FOR ESOPHAGEAL CANCER, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 30 GLOBAL MARKET FOR ESOPHAGEAL CANCER, BY REGION, 2021 (NUMBER OF PROCEDURES)
 
8 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY END USER (Page No. - 93)
    8.1 INTRODUCTION 
          TABLE 31 GLOBAL MARKET, BY END USER, 2020–2027 (USD MILLION)
    8.2 HOSPITALS 
           8.2.1 GROWING PREFERENCE FOR MINIMALLY INVASIVE SURGERIES AND ESD PROCEDURES TO SUPPORT GROWTH
                    TABLE 32 GLOBAL MARKET FOR HOSPITALS, BY COUNTRY, 2020–2027 (USD MILLION)
    8.3 SPECIALTY CLINICS 
           8.3.1 TRANSITION FROM HOSPITAL-BASED PROCEDURES TO CLINIC-BASED PROCEDURES TO BOOST GROWTH
                    TABLE 33 GLOBAL MARKET FOR SPECIALTY CLINICS, BY COUNTRY, 2020–2027 (USD MILLION)
    8.4 AMBULATORY SURGICAL CENTERS 
           8.4.1 GROWTH IN ASC SEGMENT DRIVEN BY INCREASING NUMBER OF OUTPATIENT VISITS
                    TABLE 34 GLOBAL MARKET FOR AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2020–2027 (USD MILLION)
    8.5 OTHER END USERS 
          TABLE 35 GLOBAL MARKET FOR OTHER END USERS, BY COUNTRY, 2020–2027 (USD MILLION)
 
9 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY REGION (Page No. - 100)
    9.1 INTRODUCTION 
          FIGURE 34 GLOBAL MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
          TABLE 36 GLOBAL MARKET, BY REGION, 2020–2027 (USD MILLION)
    9.2 NORTH AMERICA 
          FIGURE 35 NORTH AMERICA: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SNAPSHOT
          TABLE 37 NORTH AMERICA: MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 38 NORTH AMERICA: MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
          TABLE 39 NORTH AMERICA: MARKET, BY INDICATION, 2020–2027 (USD MILLION)
          TABLE 40 NORTH AMERICA: MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.2.1 US
                    9.2.1.1 US is largest market for endoscopic submucosal dissection products
                                TABLE 41 US: MACROECONOMIC INDICATORS
                                TABLE 42 US: MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                TABLE 43 US: MARKET, BY INDICATION, 2020–2027 (USD MILLION)
                                TABLE 44 US: MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.2.2 CANADA
                    9.2.2.1 Slower healthcare development in Canada over past decade to restrain growth
                                TABLE 45 AGE-STANDARDIZED INCIDENCE RATES (ASIR) FOR SELECTED CANCERS IN MEN AND WOMEN IN CANADA, 2020 VS. 2040
                                TABLE 46 CANADA: MACROECONOMIC INDICATORS
                                TABLE 47 CANADA: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                TABLE 48 CANADA: MARKET, BY INDICATION, 2020–2027 (USD MILLION)
                                TABLE 49 CANADA: MARKET, BY END USER, 2020–2027 (USD MILLION)
    9.3 EUROPE 
          TABLE 50 EUROPE: MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 51 EUROPE: MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
          TABLE 52 EUROPE: MARKET, BY INDICATION, 2020–2027 (USD MILLION)
          TABLE 53 EUROPE: MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.3.1 GERMANY
                    9.3.1.1 Germany to account for largest share of European market
                                TABLE 54 GERMANY: MACROECONOMIC INDICATORS
                                TABLE 55 GERMANY: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                TABLE 56 GERMANY: MARKET, BY INDICATION, 2020–2027 (USD MILLION)
                                TABLE 57 GERMANY: MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.3.2 FRANCE
                    9.3.2.1 High-quality healthcare system offering coverage to all citizens to support market growth
                                TABLE 58 FRANCE: MACROECONOMIC INDICATORS
                                TABLE 59 FRANCE: MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                TABLE 60 FRANCE: MARKET, BY INDICATION, 2020–2027 (USD MILLION)
                                TABLE 61 FRANCE: MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.3.3 UK
                    9.3.3.1 Investments by hospitals to purchase new and advanced endoscopic submucosal dissection equipment to propel market
                                TABLE 62 UK: MACROECONOMIC INDICATORS
                                TABLE 63 UK: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                TABLE 64 UK: MARKET, BY INDICATION, 2020–2027 (USD MILLION)
                                TABLE 65 UK: MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.3.4 ITALY
                    9.3.4.1 Receptivity of government toward high-quality and technologically advanced equipment to foster growth
                                TABLE 66 ITALY: MACROECONOMIC INDICATORS
                                TABLE 67 ITALY: MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                TABLE 68 ITALY: MARKET, BY INDICATION, 2020–2027 (USD MILLION)
                                TABLE 69 ITALY: MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.3.5 SPAIN
                    9.3.5.1 Rising prevalence of cancer to drive market growth
                                TABLE 70 SPAIN: MACROECONOMIC INDICATORS
                                TABLE 71 SPAIN: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                TABLE 72 SPAIN: MARKET, BY INDICATION, 2020–2027 (USD MILLION)
                                TABLE 73 SPAIN: MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.3.6 REST OF EUROPE
                    TABLE 74 ROE: MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                    TABLE 75 ROE: MARKET, BY INDICATION, 2020–2027 (USD MILLION)
                    TABLE 76 ROE: MARKET, BY END USER, 2020–2027 (USD MILLION)
    9.4 ASIA PACIFIC 
          FIGURE 36 ASIA PACIFIC: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SNAPSHOT
          TABLE 77 ASIA PACIFIC: MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 78 ASIA PACIFIC: MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
          TABLE 79 ASIA PACIFIC: MARKET, BY INDICATION, 2020–2027 (USD MILLION)
          TABLE 80 ASIA PACIFIC: MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.4.1 JAPAN
                    9.4.1.1 Supportive medical device reimbursement policies to drive market growth
                                TABLE 81 JAPAN: MACROECONOMIC INDICATORS
                                TABLE 82 JAPAN: MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                TABLE 83 JAPAN: MARKET, BY INDICATION, 2020–2027 (USD MILLION)
                                TABLE 84 JAPAN: MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.4.2 CHINA
                    9.4.2.1 Large patient population and strong need for healthcare infrastructure improvements to boost market growth
                                TABLE 85 CHINA: MACROECONOMIC INDICATORS
                                TABLE 86 CHINA: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                TABLE 87 CHINA: MARKET, BY INDICATION, 2020–2027 (USD MILLION)
                                TABLE 88 CHINA: MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.4.3 INDIA
                    9.4.3.1 Favorable government initiatives for healthcare infrastructure improvements to support market growth
                                TABLE 89 INDIA: MACROECONOMIC INDICATORS
                                TABLE 90 INDIA: MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                TABLE 91 INDIA: MARKET, BY INDICATION, 2020–2027 (USD MILLION)
                                TABLE 92 INDIA: MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.4.4 REST OF ASIA PACIFIC
                    TABLE 93 ROAPAC: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                    TABLE 94 ROAPAC: MARKET, BY INDICATION, 2020–2027 (USD MILLION)
                    TABLE 95 ROAPAC: MARKET, BY END USER, 2020–2027 (USD MILLION)
    9.5 LATIN AMERICA 
           9.5.1 INCREASING PURCHASING POWER AND HEALTHCARE AFFORDABILITY WILL FAVOR MARKET GROWTH
                    TABLE 96 LATIN AMERICA: MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                    TABLE 97 LATIN AMERICA: MARKET, BY INDICATION, 2020–2027 (USD MILLION)
                    TABLE 98 LATIN AMERICA: MARKET, BY END USER, 2020–2027 (USD MILLION)
    9.6 MIDDLE EAST AND AFRICA 
           9.6.1 HEALTHCARE INFRASTRUCTURAL ADVANCEMENTS WILL CREATE NEED FOR HOSPITAL EQUIPMENT AND MEDICAL DEVICES
                    TABLE 99 MIDDLE EAST & AFRICA: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                    TABLE 100 MIDDLE EAST & AFRICA: MARKET, BY INDICATION, 2020–2027 (USD MILLION)
                    TABLE 101 MIDDLE EAST & AFRICA: MARKET, BY END USER, 2020–2027 (USD MILLION)
 
10 COMPETITIVE LANDSCAPE (Page No. - 138)
     10.1 INTRODUCTION 
     10.2 STRATEGIES ADOPTED BY KEY PLAYERS 
     10.3 REVENUE ANALYSIS OF KEY MARKET PLAYERS 
            FIGURE 37 REVENUE ANALYSIS OF KEY PLAYERS OPERATING IN ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET
     10.4 MARKET SHARE ANALYSIS 
            FIGURE 38 GLOBAL MARKET SHARE, BY KEY PLAYER (2021)
     10.5 COMPANY FOOTPRINT ANALYSIS 
             10.5.1 FOOTPRINT OF COMPANIES, BY PRODUCT
             10.5.2 FOOTPRINT OF COMPANIES, BY END USER
             10.5.3 FOOTPRINT OF COMPANIES, BY REGION
     10.6 COMPANY EVALUATION MATRIX 
             10.6.1 STARS
             10.6.2 EMERGING LEADERS
             10.6.3 PERVASIVE PLAYERS
             10.6.4 PARTICIPANTS
                        FIGURE 39 GLOBAL MARKET: COMPANY EVALUATION MATRIX
     10.7 COMPETITIVE BENCHMARKING 
             TABLE 102 GLOBAL MARKET: KEY START-UPS/SMES
     10.8 COMPETITIVE SCENARIO 
             10.8.1 PRODUCT LAUNCHES
                        TABLE 103 GLOBAL MARKET: PRODUCT LAUNCHES (JANUARY 2019–DECEMBER 2022)
             10.8.2 DEALS
                        TABLE 104 MARKET: DEALS (JANUARY 2019–DECEMBER 2022)
             10.8.3 OTHER DEVELOPMENTS
                        TABLE 105 GLOBAL MARKET: OTHER DEVELOPMENTS (JANUARY 2019–DECEMBER 2022)
 
11 COMPANY PROFILES (Page No. - 150)
(Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)*
     11.1 KEY PLAYERS 
             11.1.1 OLYMPUS CORPORATION
                        TABLE 106 OLYMPUS CORPORATION: BUSINESS OVERVIEW
                        FIGURE 40 COMPANY SNAPSHOT: OLYMPUS CORPORATION (2022)
             11.1.2 FUJIFILM HOLDINGS CORPORATION
                        TABLE 107 FUJIFILM HOLDINGS CORPORATION: BUSINESS OVERVIEW
                        FIGURE 41 COMPANY SNAPSHOT: FUJIFILM HOLDINGS CORPORATION (2021)
             11.1.3 BOSTON SCIENTIFIC CORPORATION
                        TABLE 108 BOSTON SCIENTIFIC CORPORATION: BUSINESS OVERVIEW
                        FIGURE 42 COMPANY SNAPSHOT: BOSTON SCIENTIFIC CORPORATION (2021)
             11.1.4 MEDTRONIC
                        TABLE 109 MEDTRONIC: BUSINESS OVERVIEW
                        FIGURE 43 COMPANY SNAPSHOT: MEDTRONIC (2022)
             11.1.5 SUMITOMO BAKELITE CO., LTD.
                        TABLE 110 SUMITOMO BAKELITE CO., LTD.: BUSINESS OVERVIEW
                        FIGURE 44 COMPANY SNAPSHOT: SUMITOMO BAKELITE CO., LTD. (2021)
             11.1.6 CREO MEDICAL GROUP PLC
                        TABLE 111 CREO MEDICAL GROUP PLC: BUSINESS OVERVIEW
                        FIGURE 45 COMPANY SNAPSHOT: CREO MEDICAL GROUP PLC (2021)
             11.1.7 HOYA CORPORATION
                        TABLE 112 HOYA CORPORATION: BUSINESS OVERVIEW
                        FIGURE 46 COMPANY SNAPSHOT: HOYA CORPORATION (2022)
             11.1.8 CONMED CORPORATION
                        TABLE 113 CONMED CORPORATION: BUSINESS OVERVIEW
                        FIGURE 47 COMPANY SNAPSHOT: CONMED CORPORATION (2021)
             11.1.9 STERIS PLC
                        TABLE 114 STERIS PLC: BUSINESS OVERVIEW
                        FIGURE 48 COMPANY SNAPSHOT: STERIS PLC (2022)
             11.1.10 MTW ENDOSKOPIE MANUFAKTUR
                        TABLE 115 MTW ENDOSKOPIE MANUFAKTUR: BUSINESS OVERVIEW
     11.2 OTHER PLAYERS 
             11.2.1 OVESCO ENDOSCOPY AG
                        TABLE 116 OVESCO ENDOSCOPY AG: BUSINESS OVERVIEW
             11.2.2 ZEON MEDICAL INC.
                        TABLE 117 ZEON MEDICAL INC.: BUSINESS OVERVIEW
             11.2.3 MICRO-TECH ENDOSCOPY
                        TABLE 118 MICRO-TECH ENDOSCOPY: BUSINESS OVERVIEW
             11.2.4 KARL STORZ SE & CO. KG
                        TABLE 119 KARL STORZ SE & CO. KG.: BUSINESS OVERVIEW
             11.2.5 COOK MEDICAL
                        TABLE 120 COOK MEDICAL: BUSINESS OVERVIEW
             11.2.6 LEO MEDICAL CO., LTD.
                        TABLE 121 LEO MEDICAL CO., LTD.: BUSINESS OVERVIEW
             11.2.7 ERBE ELEKTROMEDIZIN GMBH
                        TABLE 122 ERBE ELEKTROMEDIZIN GMBH: BUSINESS OVERVIEW
             11.2.8 TAEWOONG MEDICAL CO., LTD.
                        TABLE 123 TAEWOONG MEDICAL CO., LTD.: BUSINESS OVERVIEW
             11.2.9 DCC HEALTHCARE LIMITED
                        TABLE 124 DCC HEALTHCARE LIMITED: BUSINESS OVERVIEW
             11.2.10 KOSSEN CO., LTD.
                        TABLE 125 KOSSEN CO., LTD.: BUSINESS OVERVIEW
             11.2.11 INNOVAMEDICA S.P.A.
                        TABLE 126 INNOVAMEDICA S.P.A.: BUSINESS OVERVIEW
             11.2.12 JIANGSU VEDKANG MEDICAL SCIENCE AND TECHNOLOGY CO., LTD.
                        TABLE 127 JIANGSU VEDKANG MEDICAL SCIENCE AND TECHNOLOGY CO., LTD.: BUSINESS OVERVIEW
             11.2.13 HANGZHOU AGS MEDICAL TECHNOLOGICAL CO., LTD.
                        TABLE 128 HANGZHOU AGS MEDICAL TECHNOLOGICAL CO., LTD.: BUSINESS OVERVIEW
             11.2.14 BEIJING ZKSK TECHNOLOGY CO., LTD.
                        TABLE 129 BEIJING ZKSK TECHNOLOGY CO., LTD.: BUSINESS OVERVIEW
 
*Details on Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)* might not be captured in case of unlisted companies.
 
12 APPENDIX (Page No. - 194)
     12.1 DISCUSSION GUIDE 
     12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 
     12.3 CUSTOMIZATION OPTIONS 
     12.4 RELATED REPORTS 
     12.5 AUTHOR DETAILS 

This study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify the segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies.

Secondary Research

This research study involved the usage of comprehensive secondary sources; directories; databases such as Bloomberg Business, Factiva, and Dun & Bradstreet; white papers; annual reports; company house documents; investor presentations; and SEC filings of companies. Secondary research was used to identify and collect information useful for an extensive, technical, market-oriented, and commercial study of the endoscopic submucosal dissection market. It was also used to obtain important information about the key players, market classification and segmentation according to industry trends to the bottommost level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side and demand side are detailed below.

A breakdown of the primary respondents is provided below:

Breakdown of Primary Interviews: Supply-Side Participants- by Company Type, Designation, and Region

Endoscopic Submucosal Dissection Market Size, and Share

Note 1: C-level primaries include CEOs, COOs, CTOs, and VPs.

Note 2: Other primaries include sales managers, marketing managers, and product managers.

Note 3: Companies are classified into tiers based on their total revenue. As of 2020: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = <USD 500 million.

To know about the assumptions considered for the study, download the pdf brochure

Breakdown of Primary Interviews: Demand-Side Participants by End-User, Designation, and Region

Endoscopic Submucosal Dissection Market Size, and Share

Note: Others include department heads, research scientists, and professors.

Market Size Estimation

The total size of the endoscopic submucosal dissection market was arrived at after data triangulation from three different approaches, as mentioned below. After each approach, the weighted average of all approaches was taken based on the level of assumptions used in each approach.

Data Triangulation

After arriving at the market size, the total market was divided into several segments and sub-segments. To complete the overall market engineering process and arrive at the exact statistics for all segments and sub-segments, data triangulation and market breakdown procedures were employed, wherever applicable. The following figure shows the market validation, source structure, and data triangulation methodology implemented in this report’s market engineering process.

Objectives of the Study

  • To describe, analyze, and forecast the endoscopic submucosal dissection market by product, indication, end user, and region
  • To describe and forecast the endoscopic submucosal dissection market for key regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa
  • To provide detailed information regarding the drivers, restraints, opportunities, and challenges influencing the growth of the endoscopic submucosal dissection market
  • To strategically analyze the ecosystem, regulations, patenting trend, value chain, Porter’s five forces, and prices pertaining to the market under study
  • To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for market players
  • To profile key players and comprehensively analyze their market shares and core competencies in the endoscopic submucosal dissection market
  • To analyze competitive developments such as collaborations, acquisitions, product launches, expansions, and R&D activities in the endoscopic submucosal dissection market

Available customizations

With the given market data, MarketsandMarkets offers customizations as per your company’s specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to 5)

Geographic Analysis

  • Further breakdown of the RoE endoscopic submucosal dissection market into Austria, Finland, and others
  • Further breakdown of the Latin America endoscopic submucosal dissection market into Brazil, Mexico, Argentina, Colombia, Chile, and others

Competitive Landscape Assessment

Market share analysis for the North America and Europe region, which provides market shares of the top 3–5 key players in the endoscopic submucosal dissection market

  • Competitive leadership mapping for established players in the US

Key areas which can be focused in the ESD endoscopy market by a CEO in the Business Strategy

Market analysis: The CEO would need to analyze the market to understand the size, growth rate, and competitive landscape. This would involve identifying key trends and drivers in the market, as well as potential opportunities and threats.

Product development: The CEO would need to consider the company's product portfolio and identify areas for potential expansion or improvement. This might involve developing new products or features that meet the needs of customers or address unmet needs in the market.

Sales and marketing: The CEO would need to develop a sales and marketing strategy to drive growth and increase market share. This might involve investing in advertising, attending trade shows, or partnering with other companies to reach new customers.

Partnerships and collaborations: The CEO might also consider partnering with other companies to expand the company's capabilities or enter new markets. For example, the company might partner with a medical device manufacturer to develop new products or with a healthcare provider to expand distribution channels.

Some recent examples of growth strategies in the ESD endoscopy market include

Product innovation: Companies such as Olympus, Pentax Medical, and Fujifilm have introduced new products that offer advanced features such as high-definition imaging, advanced visualization, and artificial intelligence (AI) capabilities.

Mergers and acquisitions: In 2020, Boston Scientific acquired the majority stake in Preventice Solutions, a provider of remote monitoring and diagnostics for cardiac arrhythmias. This acquisition expanded Boston Scientific's capabilities in digital health and remote patient monitoring, which could be leveraged in the ESD endoscopy market.

Partnerships and collaborations: In 2019, Cook Medical and Taewoong Medical formed a strategic partnership to expand their product portfolios and market presence in the ESD endoscopy market. The partnership leveraged Cook Medical's expertise in endoscopic devices and Taewoong Medical's expertise in stents and other medical devices.

Top use cases including existing and futuristic for ESD endoscopy market

  • Early detection and diagnosis of gastrointestinal cancers
  • Treatment of early-stage gastrointestinal cancers
  • Removal of precancerous polyps
  • Endoscopic resection of gastrointestinal tumors
  • Management of gastrointestinal bleeding
  • Treatment of esophageal strictures
  • Treatment of achalasia
  • Removal of foreign bodies from the gastrointestinal tract
  • Treatment of inflammatory bowel disease
  • Endoscopic sleeve gastroplasty for weight loss
  • Endoscopic treatment of gastroesophageal reflux disease (GERD)
  • Endoscopic retrograde cholangiopancreatography (ERCP) for the treatment of biliary and pancreatic disorders
  • Endoscopic ultrasound for the diagnosis and staging of gastrointestinal cancers
  • Endoscopic mucosal resection (EMR) for the removal of benign and early-stage malignant tumors
  • Endoscopic submucosal tunneling for the treatment of submucosal tumors
  • Endoscopic dilation for the treatment of gastrointestinal strictures
  • Endoscopic injection of botulinum toxin for the treatment of achalasia
  • Endoscopic placement of stents for the treatment of gastrointestinal strictures and obstructions
  • Endoscopic hemostasis for the treatment of gastrointestinal bleeding
  • Endoscopic band ligation for the treatment of esophageal varices
  • Endoscopic submucosal dissection (ESD) for the removal of early-stage gastrointestinal cancers
  • Endoscopic mucosal ablation for the treatment of Barrett's esophagus
  • Endoscopic radiofrequency ablation for the treatment of Barrett's esophagus and early-stage esophageal cancers
  • Endoscopic cryotherapy for the treatment of early-stage esophageal cancers
  • Endoscopic full-thickness resection for the removal of gastrointestinal tumors
  • Endoscopic submucosal tunneling with endoscopic closure for the treatment of gastrointestinal perforations
  • Endoscopic suturing for the closure of gastrointestinal perforations and leaks
  • Endoscopic ultrasound-guided ablation for the treatment of pancreatic and biliary tumors
  • Endoscopic ultrasound-guided drainage for the treatment of pancreatic pseudocysts and abscesses
  • Endoscopic ultrasound-guided gastrojejunostomy for the treatment of gastric outlet obstruction
  • Endoscopic ultrasound-guided portal pressure measurement for the diagnosis of portal hypertension
  • Endoscopic mucosal resection with cap-assisted aspiration for the removal of large colorectal polyps
  • Endoscopic ultrasound-guided fine needle aspiration for the diagnosis of pancreatic and biliary tumors
  • Endoscopic ultrasound-guided fiducial marker placement for the delivery of stereotactic radiotherapy
  • Endoscopic submucosal dissection with en bloc retrieval for the diagnosis of submucosal tumors
  • Endoscopic removal of intraluminal cysts
  • Endoscopic treatment of esophageal diverticula
  • Endoscopic treatment of Zenker's diverticulum
  • Endoscopic mucosal resection with underwater endoscopic mucosal resection for the removal of rectal lesions
  • Endoscopic ultrasound-guided gastroenterostomy for the treatment of malignant gastric outlet obstruction
  • Endoscopic ultrasound-guided biliary drainage for the treatment of obstructive jaundice
  • Endoscopic ultrasound-guided pancreatic duct drainage for the treatment of pancreatic duct obstruction
  • Endoscopic ultrasound-guided hepaticogastrostomy for the treatment of bile duct obstruction

Niche threats/restraints for ESD Endoscopy Business in enterprise?

While the ESD (Endoscopic Submucosal Dissection) endoscopy market presents several growth opportunities, there are also some potential threats and restraints that could affect the business. Here are some of the niche threats and restraints for ESD endoscopy business in enterprise

  • High cost of ESD procedures compared to conventional endoscopic procedures
  • Limited availability of skilled endoscopists who can perform ESD procedures
  • Potential complications associated with ESD procedures, such as perforation, bleeding, and post-procedural stricture formation
  • Lack of reimbursement coverage for ESD procedures in some regions
  • Competition from alternative treatment options, such as laparoscopic or open surgical procedures
  • Stringent regulatory requirements for ESD devices and procedures, which may limit product innovation and development
  • Ethical and legal concerns around performing ESD procedures on elderly or high-risk patients
  • Limited awareness among patients and healthcare providers about the benefits of ESD procedures, which may impact adoption rates
  • Challenges in maintaining high-quality endoscopic imaging and visualization during ESD procedures, which may affect clinical outcomes
  • Limited access to advanced endoscopic equipment and technologies in some regions, which may affect the ability to perform ESD procedures safely and effectively.

Recent examples of niche threats/restraints for ESD endoscopy business in enterprise

Lack of reimbursement coverage: In the United States, ESD procedures are not covered by Medicare, which is the largest health insurance provider in the country. This limits access to ESD procedures for many patients, and may also affect the profitability of ESD endoscopy businesses. However, some private insurance providers are starting to cover ESD procedures, which may help to improve access and reimbursement.

Regulatory requirements: In Japan, which is one of the largest markets for ESD endoscopy, regulatory requirements for ESD devices and procedures are becoming increasingly stringent. This has led to delays in device approvals and may also limit the ability of companies to innovate and develop new ESD technologies.

Competition from alternative treatment options: In some cases, laparoscopic or open surgical procedures may be a more effective or cost-efficient treatment option than ESD. This competition can limit the adoption of ESD procedures and may also impact the profitability of ESD endoscopy businesses.

Limited availability of skilled endoscopists: ESD procedures require a high level of technical skill and experience, which may limit the availability of skilled endoscopists who can perform these procedures. This can be a barrier to entry for new ESD endoscopy businesses, and may also limit the growth of existing businesses.

Ethical and legal concerns: In some cases, performing ESD procedures on elderly or high-risk patients may raise ethical and legal concerns around patient safety and informed consent. This can limit the adoption of ESD procedures and may also lead to negative publicity for ESD endoscopy businesses.

Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Request Customization

Instant Answers with GPT - Ask Now!

Ask real questions. Get complete answers !
Report Code
MD 8538
Published ON
Jan, 2023
REQUEST FREE SAMPLE REPORT
Choose License Type
BUY NOW
Inquire Before Buying
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Endoscopic Submucosal Dissection Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2023 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status Website Feedback